Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 11/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020161 | 0.85 | BCHE (0.66) | BCHEHTR2A | |
| SCHEMBL4022974 | 0.84 | BCHE (0.64) | BCHEHTR2ASIGMAR1TMEM97CARM1 | |
| SCHEMBL4029991 | 0.84 | BCHE (0.64) | BCHESIGMAR1TMEM97CARM1PRMT6 | |
| SCHEMBL4021849 | 0.84 | BCHE (0.65) | BCHESIGMAR1TMEM97CARM1PRMT6 | |
| SCHEMBL4020320 | 0.82 | BCHE (0.66) | BCHESIGMAR1TMEM97CARM1PRMT6 | |
| SCHEMBL4025407 | 0.80 | BCHE (1.00) | BCHEHTR2ATMEM97 | |
| SCHEMBL4024108 | 0.78 | BCHE (0.63) | BCHEHTR2ASIGMAR1TMEM97CARM1 | |
| SCHEMBL4023211 | 0.78 | BCHE (0.63) | BCHEHTR2ASIGMAR1TMEM97CARM1 | |
| SCHEMBL4020617 | 0.75 | BCHE (0.57) | BCHESIGMAR1TMEM97CARM1PRMT6 | |
| SCHEMBL4024111 | 0.73 | BCHE (0.57) | BCHEHTR2ASIGMAR1TMEM97CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446400-B1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO LTD (KR) | 2009-01-28 | — | — | EP | claimed |
| US-7288552-B2 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | STC NARA CO., LTD. (KR) | 2007-10-30 | — | — | US | claimed |
| EP-1446400-A4 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO LTD (KR) | 2005-06-01 | — | — | EP | claimed |
| US-20050043316-A1 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | STC NARA CO., LTD. (KR) | 2005-02-24 | — | — | US | claimed |
| EP-1446400-A1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC Nara Co. Ltd. (KR) | 2004-08-18 | — | — | EP | claimed |
| WO-2003033489-A1 | PIPERIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S DISEASE CONTAINING THE SAME | STC NARA CO., LTD. (KR) | 2003-04-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043316-A1 | Piperidine derivatives, process for preparation thereof, and pharmaceutical composition for alzheimer's disease containing the same | APP, ACHE, PSEN1 | BCHE 7/4885HTR2A 1505/4885MAPT 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.